Table 4 Treatment-related adverse events
n(%) | All grade | Grade 3–4 | ||||
|---|---|---|---|---|---|---|
TACE-TC(n = 46) | TACE-T(n = 42) | P | TACE-TC(n = 46) | TACE-T(n = 42) | P | |
Hypertension | 10(21.7) | 13(31.0) | 0.326 | 2(4.3) | 4(9.5) | 0.419 |
Diarrhea | 8(17.4) | 7(16.7) | 0.928 | 1(2.1) | 2(4.8) | 0.604 |
Appetite decreased | 7(15.2) | 5(11.9) | 0.651 | 0 | 0 | - |
Fatigue | 5(10.9) | 3(7.1) | 0.716 | 0 | 0 | - |
RCCEP | 11(23.9) | 0 | 0.001 | 0 | 0 | - |
Hypothyroidism | 4(8.6) | 0 | 0.118 | 0 | 0 | - |
Hoarseness | 0 | 1(2.4) | 0.477 | 0 | 0 | - |
Hand–foot skin reaction | 4(8.6) | 9(21.4) | 0.133 | 1(2.1) | 2(4.8) | 0.604 |
Hemorrhagic cystitis | 1(2.2) | 0 | 1.000 | 0 | 0 | - |
Thrombocytopaenia | 12(26.1) | 14(33.3) | 0.457 | 3(6.5) | 2(4.8) | 1.000 |
Neutropaenia | 14(30.4) | 10(23.8) | 0.486 | 0 | 1(2.4) | 0.477 |
Decreased WBC count | 11(23.9) | 9(21.4) | 0.781 | 1(2.1) | 0 | 1.000 |
Lymphocytopenia | 12(26.1) | 10(23.8) | 0.805 | 2(4.3) | 0 | 0.495 |
Elevated AST | 19(41.3) | 20(47.6) | 0.551 | 4(8.7) | 5(11.9) | 0.731 |
Elevated ALT | 14(30.4) | 13(31.0) | 0.958 | 2(4.3) | 0 | 0.495 |
Elevated bilirubin | 21(45.7) | 18(42.9) | 0.792 | 0 | 3(7.1) | 0.105 |